() Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

PRE-TAX PROFIT(Q) At JPY 67.45 MM has Fallen at -52.31%
ROCE(HY) Lowest at 9.23%
DEBTORS TURNOVER RATIO(HY) Lowest at 1.46%

With ROE of 14.68%, it has a very attractive valuation with a 4.04 Price to Book Value

Consistent Underperformance against the benchmark over the last 3 years

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

JPY 9,673 Million (Micro Cap)

P/E

28.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.84

Return on Equity

9.44%

Price to Book

3.64

Revenue and Profits:

Net Sales:

701 Million

(Quarterly Results - Jun 2025)

Net Profit:

43 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-15.63%

6 Months

-21.9%

1 Year

-41.93%

2 Years

-62.1%

3 Years

-68.67%

4 Years

-66.89%

5 Years

0.0%

StemCell Institute for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

14.56%

EBIT Growth (5y)

22.63%

EBIT to Interest (avg)

100.00

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-1.03

Sales to Capital Employed (avg)

0.91

Tax Ratio

31.80%

Dividend Payout Ratio

66.37%

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

10.52%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

4.04

EV to EBIT

18.92

EV to EBITDA

14.48

EV to Capital Employed

-116.15

EV to Sales

2.96

PEG Ratio

1.12

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

14.68%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

Bullish

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 9.75% vs -4.20% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -6.10% vs -32.50% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "701.00",
          "val2": "638.70",
          "chgp": "9.75%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "98.90",
          "val2": "95.40",
          "chgp": "3.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.40",
          "val2": "1.00",
          "chgp": "40.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "43.10",
          "val2": "45.90",
          "chgp": "-6.10%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "93.20%",
          "val2": "93.50%",
          "chgp": "-0.03%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 7.98% vs 18.64% in Mar 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is 24.05% vs 57.07% in Mar 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,679.20",
          "val2": "2,481.20",
          "chgp": "7.98%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "546.30",
          "val2": "534.30",
          "chgp": "2.25%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.20",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "1.70",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "385.80",
          "val2": "311.00",
          "chgp": "24.05%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "156.20%",
          "val2": "166.80%",
          "chgp": "-1.06%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

701.00

638.70

9.75%

Operating Profit (PBDIT) excl Other Income

98.90

95.40

3.67%

Interest

1.40

1.00

40.00%

Exceptional Items

0.00

Consolidate Net Profit

43.10

45.90

-6.10%

Operating Profit Margin (Excl OI)

93.20%

93.50%

-0.03%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is 9.75% vs -4.20% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -6.10% vs -32.50% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Mar'25

Mar'25

Mar'24

Change(%)

Net Sales

2,679.20

2,481.20

7.98%

Operating Profit (PBDIT) excl Other Income

546.30

534.30

2.25%

Interest

1.20

0.00

Exceptional Items

0.00

1.70

-100.00%

Consolidate Net Profit

385.80

311.00

24.05%

Operating Profit Margin (Excl OI)

156.20%

166.80%

-1.06%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Mar 2025 is 7.98% vs 18.64% in Mar 2024

Consolidated Net Profit

YoY Growth in year ended Mar 2025 is 24.05% vs 57.07% in Mar 2024

All Annual Results

Company CV

About StemCell Institute

StemCell Institute

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available